Article
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Cancer - 15 Jun 2015
Yu Helena A, Sima Camelia S, Hellmann Matthew D, Naidoo Jarushka, Busby Natalie, Rodriguez Katherine, Riely Gregory J, Kris Mark G
Abstract excerpt
BACKGROUND: Prognostic variables are independently associated with survival and are fundamental to clinical trial design. In the current study, the authors evaluated the impact of stage of disease at the time of the initial diagnosis on overall survival (OS) in 2 independent, oncogene-defined cohorts. METHODS: All patients with epidermal growth factor receptor (EGFR)-mutant and KRAS-mutant metastatic lung...
Topics
- Adenocarcinoma
- Adenocarcinoma of Lung
- Adult
- Aged
- Aged, 80 and over
- ErbB Receptors
- Female
- Genes, ras
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Mutation
- Neoplasm Metastasis